Literature DB >> 9972992

Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology.

F Wolfe1, M Lassere, D van der Heijde, G Stucki, M Suarez-Almazor, T Pincus, K Eberhardt, T K Kvien, D Symmons, A Silman, P van Riel, P Tugwell, M Boers.   

Abstract

Observational and longitudinal observational studies (LOS) provide essential information about the course and outcome of rheumatic disorders that cannot be provided by randomized controlled trials, and they constitute the major clinical scientific communication in rheumatology. There has been no consensus as to the full and appropriate content of LOS. This report defines a core set of domains and reporting requirements for LOS. At the 1998 OMERACT IV Conference a consensus process evaluated the literature of rheumatology in light of the constructs, variables, and outcomes of rheumatology by using introductory lectures, nominal groups, and plenary sessions. The result of this process was to identify 5 "core" domains that should be included in every LOS: Health Status, Disease Process, Damage, Mortality, and Toxicity/Adverse Reactions. Two additional domains, Work Disability and Costs, were recognized as important, but need not be used in all LOS. Eleven subdomains were identified that divided the domains into convenient clinical and conceptual units. A set of reporting requirements was also determined. The core recommendations, which follow on the WHO ICIDH-2 outline, are not disease-specific; the substitution of different "disease process" and "damage" measures make them suitable for many rheumatic disorders. The core set is intended to serve as a core for LOS in almost all rheumatic conditions.

Entities:  

Mesh:

Year:  1999        PMID: 9972992

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  30 in total

1.  Sicca symptoms, saliva and tear production, and disease variables in 636 patients with rheumatoid arthritis.

Authors:  T Uhlig; T K Kvien; J L Jensen; T Axéll
Journal:  Ann Rheum Dis       Date:  1999-07       Impact factor: 19.103

Review 2.  Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics.

Authors:  Daniel Aletaha; Josef S Smolen
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

Review 3.  Interpreting radiographic data in rheumatoid arthritis.

Authors:  P A Ory
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

4.  Large scale evidence and replication: insights from rheumatology and beyond.

Authors:  J P A Ioannidis
Journal:  Ann Rheum Dis       Date:  2004-09-30       Impact factor: 19.103

Review 5.  Impairment measures in rheumatic disorders for rehabilitation medicine and allied health care: a systematic review.

Authors:  Raymond A H M Swinkels; Lex M Bouter; Rob A B Oostendorp; Cornelia H M van den Ende
Journal:  Rheumatol Int       Date:  2005-06-24       Impact factor: 2.631

6.  Health status in rheumatoid arthritis over 7 years.

Authors:  A Boonen; R Landewé
Journal:  Ann Rheum Dis       Date:  2005-02       Impact factor: 19.103

7.  Occupational work and quality of life in osteoarthritis patients.

Authors:  Elzbieta Łastowiecka; Joanna Bugajska; Andrzej Najmiec; Maria Rell-Bakalarska; Irena Bownik; Anna Jedryka-Góral
Journal:  Rheumatol Int       Date:  2006-11-09       Impact factor: 2.631

Review 8.  Open-label extension studies: do they provide meaningful information on the safety of new drugs?

Authors:  Richard O Day; Kenneth M Williams
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Predictors of treatment failure and mortality in native septic arthritis.

Authors:  Jose R Maneiro; Alejandro Souto; Evelin C Cervantes; Antonio Mera; Loreto Carmona; Juan J Gomez-Reino
Journal:  Clin Rheumatol       Date:  2014-12-13       Impact factor: 2.980

10.  Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.

Authors:  L Gossec; M Dougados; P Goupille; A Cantagrel; J Sibilia; O Meyer; J Sany; J-P Daurès; B Combe
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.